Global Protein Expression Market Report 2021: COVID-19

0


New York, September 28, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Protein Expression Global Market Report 2021: COVID-19 Growth And Change To 2030” – https://www.reportlinker.com / p06151569 / ? utm_source = GNW
01 billion in 2020 to 2.13 billion dollars in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is primarily driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges. The market is expected to reach $ 3.03 billion in 2025 at a CAGR of 9.2%.

The protein expression market includes the sale of protein expression vectors, competent cells, reagents, equipment and related services. Protein expression is a process in which proteins are synthesized, modified, regulated and controlled in living organisms depending on the host cell.

Protein expression included yeast expression, insect and bacterial expression, algae expression, and mammalian cell expression.

The protein expression market covered in this report is segmented by protein expression into yeast expression, mammalian expression, algal expression, insect expression, bacterial expression, cell-free expression. It is also segmented by end use into pharmaceutical and biotechnology companies, academic research, contract research organizations; by product in reagents, competent cells, expression vectors, services, instruments and by application in therapeutic and industrial research.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.

Government regulations relating to therapeutic proteins and the production of biologics may hamper the growth of the protein expression market. Government biologics regulations must undergo rigorous preclinical and clinical testing before regulatory approval, and a lengthy process of approving biologics with regard to the health and safety of all individuals is holding back market growth.

The marketing and distribution of biologics, including insulin, hormones, therapeutic antibodies and vaccines, depends on the success of clinical trials, which is a long, expensive and uncertain process. According to the FDA, for approval of a new biologic, under regulations (21 CFR 314.81 (b) (2) (vii) and 601.70, a clinical trial approval typically takes 10 to 12 months where companies are required to submit an annual report on the status of clinical safety, clinical efficacy, clinical pharmacology and non-clinical toxicology study.

Companies in the industry are increasingly adopting microfluidic technology to improve protein expression assays to reduce time, costs, manpower, and increase precision and performance. Microfluidic technology efficiently analyzes biological samples compared to traditional instruments (at the macro scale).

Microfluidic technology is used to measure protein expression on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses a microfluidic platform and is capable of synthesize proteins at a point of service to reduce cost associated with the storage and transport of therapeutic proteins.

For example, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression testing.

One of the major factors driving research and sales in the protein expression market is increasing demand for biologics to combat various genetic disorders and chronic diseases. Biologics are drugs produced from living organisms or contain components of living organisms such as proteins, tissues, genes, allergens, cells, blood components, blood and vaccines.

The increasing use of biologics (therapeutic proteins and others) to treat chronic diseases such as cancer, cardiovascular disease and genetic disorders, increases the demand for protein expression devices and equipment. According to the World Health Organization, the prevalence of chronic diseases is expected to increase by 57% worldwide by 2020.

Hence, the increasing demand for biologics is boosting the protein expression market. For example, according to an article published by Chemistry World, analysts expect the biologics market to have a market share of more than a quarter of the entire pharmaceutical market by 2020.

The global organic market is expected to grow by 9.9% during the period 2018-2024.

The protein expression market in the United States is regulated by the Food and Drug Administration (FDA) which establishes a series of guidelines for manufacturers and retailers in this industry. Within the FDA, the Center for Drug Evaluation and Research (CDER) regulates biologics under FDA 101, which includes gene therapy products and vaccines. These regulations ensure the quality, safety and efficacy of biological therapy products and accelerate innovations that make these products safer and more effective. The United States FDA has announced a fast-track initiative to review its drug and biologics policy to speed up the availability of therapies for patients with severe disease, orphan drugs for rare diseases, while preserving the safety and efficiency standards. The FDA also removed a rule (section 610.21 of the FDA code) that specified minimum activity limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies that include a provision to waive scientific advice fees, which encourage more academic groups and small businesses to come up with candidates for biologics.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.
Read the full report: https://www.reportlinker.com/p06151569/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________



Leave A Reply

Your email address will not be published.